Tradipitant FDA approval date

The FDA approved Tradipitant (Nereus) on 30 Dec 2025.

FDA approval date
30 Dec 2025

Drug identity checked against registry records

Also recorded as Nereus; VLY-686

Included trials

TrialSponsorPhaseStatusPrimary completion
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)NCT04140695Vanda PharmaceuticalsPhase 3Terminated2020-10-14Actual
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic GastroparesisNCT04028492Vanda PharmaceuticalsPhase 3Completed2025-02-21Actual
Tradipitant in Treatment-resistant Pruritus Associated With Atopic DermatitisNCT02651714Vanda PharmaceuticalsPhase 2Completed2017-08-04Actual
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)NCT03568331Vanda PharmaceuticalsPhase 3Completed2019-12-27Actual
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion SicknessNCT06138613Vanda PharmaceuticalsPhase 3Active not recruiting2027-09-30Estimated
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion SicknessNCT05903924Vanda PharmaceuticalsPhase 3Completed2024-04-06Actual
Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessNCT04327661Vanda PharmaceuticalsPhase 3Completed2023-04-01Actual
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseNCT07446439Vanda PharmaceuticalsPhase 3Recruiting2026-12-01Estimated
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisNCT06836557Vanda PharmaceuticalsPhase 3Completed2026-03-30Actual
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessNCT03772340Vanda PharmaceuticalsPhase 2Completed2019-06-06Actual
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist UseNCT06804603Vanda PharmaceuticalsPhase 2Completed2025-10-06Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2025-12-30DayTradipitantFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA220152", "applicant_as_listed_by_fda": "VANDA PHARMS INC", "brand_names": ["NEREUS"], "active_ingredients": ["TRADIPITANT"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20251230", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026